


Meet the Speakers

The Clinical Trials Summit of Pakistan 2025

Dr. Baber Saeed Khan, MBBS, MPH, CPI, FAPCR

Currently serving as Director of the Clinical Trials Unit at the National University of Medical Sciences (NUMS), where he leads initiatives to advance Pakistan's clinical research landscape. As the founding President of the ACRP Ambassadors Club of Pakistan, he is dedicated to promoting professional development in clinical research.

Previously, Dr. Khan served as CEO of Longwood Research in the United States, where he successfully conducted 72 clinical trials as Investigator in partnership with renowned institutions such as the NIH and Harvard. His efforts to strengthen health policies and strategies have included collaborations with global organizations like the WHO. A passionate advocate for clinical research development, Dr. Khan continues to work toward elevating Pakistan's standing in the global research community.



Dr. Zainab Samad, MBBS, MHS

Ibn-e-Sina Professor of Medicine & Chair, Department of Medicine, Aga Khan University, Karachi, Pakistan

Dr. Samad graduated from the Aga Khan University MBBS program in 2000. She completed residency in Internal Medicine, a Fellowship in cardiology, and a Masters in Clinical Research at Duke University. After completing training in 2009, she served on Duke University faculty (2009-2018). She joined the Aga Khan University in 2018.

Dr. Samad's clinical and research efforts are focused on understanding the epidemiology and outcomes of heart disease. Her mentorship and educational efforts have been recognized with several awards.

An important part of her professional vision is to improve cardiovascular health in Pakistan through gender inclusive capacity building efforts that fully leverage available data resources and global connections. She is currently working on Health Data Sciences growth and development.



Meet the Speakers

The Clinical Trials Summit of Pakistan 2025

Dr. Bashir Hanif, MD, FACC, FSCAI

Dr. Hanif is a Diplomate of multiple prestigious boards, including the American Board of Internal Medicine, Cardiovascular Diseases, and Interventional Cardiology. He is also a Fellow of the American College of Cardiology and the Society of Cardiovascular Angiography and Interventions.


Currently serving as the Executive Director of Tabba Heart Institute, Dr. Hanif has been instrumental in establishing it as a center of excellence in Pakistan, pioneering advanced interventional cardiology training programs and national cardiac registries. He has also played a pivotal role in shaping cardiology education as the former Dean of the Faculty of Cardiology at CPSP and Governor of the American College of Cardiology, Pakistan Chapter.

With leadership roles in international cardiology societies

Dr. Hanif continues to drive innovation in cardiovascular research and clinical excellence with initiation of landmark Mini Framingham of South Asia – PAK SEHAT a long term 10 year follow up study of young healthy adults all over Pakistan for which enrollment has been completed and follow up is in progress. Biobanking, genetics and environmental factors will also be analyzed.

Achievements at Tabba Heart Institute:

- Executive Director
- Medical Director
- Started Cardiology Fellowship training program
- Initiated and wrote the curriculum and examination system for FCPS in Interventional Cardiology for CPSP.
- Started first ever structured Advanced Interventional Cardiology Fellowship (2 years) training program in Pakistan (2 fellows each year) at THI as well as all over Pakistan.
- Established the highest interventional volume center (coronary, structural and peripheral interventions) in private set up in Pakistan >1800 interventions /year
- Initiated and established Cardiac Registry of Pakistan (CROP) - Cath PCI Registry
- Initiated and established Heart Failure Registry of Pakistan
- Took the initiative to bring NCDR (National Cardiac Database Registry of ACC) in Pakistan, in 2012 – Registered THI as first ever international hospital. Other international hospitals were taken on board after THI/Pakistan experience by ACC management
- Awarded Platinum Quality Cardiac Care Hospital since 2012 based on NCDR by ACC data submission and bench mark reports.



Meet the Speakers

The Clinical Trials Summit of Pakistan 2025

Dr. Adeel Khoja, MBBS, MSc, PhD

Dr. Khoja is an academic researcher with over 14 years of experience in clinical and implementation research on non-communicable diseases, mainly cardiovascular diseases, including stroke. To date, Dr Khoja has 50+ publications in high-impact journals, is a reviewer of ten Pub Med indexed journals, is the associate editor of Joanna Briggs Institute Evidence Implementation Journal, and is section editor of Global Cardiovascular Disease Updates, Current Atherosclerosis Reports. His research interests focus on premature cardiac events targeting young adults, including pregnant women, as well as sex differences associated with these early cardiac events. As part of his PhD thesis, he linked three databases of South Australia to assess association of pregnancy complications and early life cardiovascular events in women less than 60 years.



As a principal or co-investigator on various local and international implementation research projects, with total funding of USD 463,027 awarded, he has been involved in the primary epidemiological studies and randomized clinical trials using mobile-based applications, monitoring and evaluating eHealth (electronic health)-based interventions, including telemedicine and eLearning. Furthermore, he has also conducted a series of comprehensive systematic reviews on coronary heart disease (CHD) comparing early versus late-onset CHD and sex differences associated with early-onset CHD. Throughout his public health career, Dr Khoja has been interacting with foreign donors, governmental and non-governmental agencies, community stakeholders, as well as collaborating with interdisciplinary teams for dissemination and translation of findings into public health policies.

Meet the Speakers


The Clinical Trials Summit of Pakistan 2025

Prof. Abdul Basit

M.B.B.S. (Pak), M.R.C.P. (UK), F.R.C.P. (Lon),
F.R.C.P. (Edin)

Professor & Head, Diabetes and Endocrine Centre, Indus Hospital and Health Network (IHHN).

- Secretary General, Diabetic Association of Pakistan (DAP) and Head, WHO Collaborating Centre for "Treatment, Education & Research in Diabetic Pregnancies".
- Vice Chairman, Health Promotion Foundation (HPF).
- Vice Chairman, Health Research Advisory Board (HRAB).
- President, Diabetes in Asia Study Group (DASG).
- Chairman, Pakistan Working Group on the Diabetic Foot (PWGDF).
- Founder Member, Pakistan Endocrine Society (PES).
- Founder Member, National Association of Diabetes Educators (NADEP).
- Former-chair, IDF MENA Region.
- Ex-Editor, Journal of Diabetology (JOD), official journal of DASG.
- More than 240 research papers have been published.



Meet the Speakers

The Clinical Trials Summit of Pakistan 2025

Dr. Shahid Pervaiz

M.B.B.S, DCP (London), Ph.D (Histopath, London); FCPS (Histopath PK), FRCPath (UK)

Dr Shahid Pervez is a Professor & Senior Consultant Histopathologist at AKUH. His major diagnostic and research interests include Breast Pathology, Neoplastic Hematopathology and Predictive Pathology. He has supervised several FCPS & PhD students and published extensively with over 260 research publications (Citations: 4583, h-index: 37 and i10-index 123) and several book chapters. He is also Editor of 'Atlas of Diagnostic & Predictive Histopathology', published by 'Springer'. He has served in various leadership positions and was elected 'Councillor' of College of Physicians & Surgeons Pakistan (CPSP) for the term 2020-2023 and is the 'Editor' of CPSP official journal (JCPSP) and CPSP newly launched journal 'JCPSP Postgraduate'. He is also 'Country Advisor & Senior Examiner of Royal College of Pathologists, UK'. He played a pivotal role in establishing vibrant and active Pathology forums and is the Founder President of 'IAP-Pakistan Division', 'Histopathology & Cytology Society of Pakistan (HCSP)' & 'SAARC Academy of Cytology & Histopathology (SACH)'. Dr Pervez also played a pivotal role in reviving 'Karachi Cancer Registry (KCR)' and is the 'Chair of KCR' and 'Vice Chair of National Steering Committee for Cancer Registry'. He is also a distinguished scholar for COMSTECH (OIC) scholar program.



Meet the Speakers

The Clinical Trials Summit of Pakistan 2025

Dr. Arash Rashidian, MD, PhD

Director of Science, Information and Dissemination, WHO Regional Office for the Eastern Mediterranean.

Professor Arash Rashidian (MD, PhD) is the Director of Science, Information and Dissemination at the WHO Regional Office for the Eastern Mediterranean. Since 2015, he has led the WHO regional agenda on evidence-informed policy making, health information systems, digital health, research promotion and governance and knowledge sharing. His career in health policy research and health system development spans 25 years and several countries.

During the COVID-19 pandemic, Dr Rashidian led the research and knowledge management pillar of the WHO response management team in the Eastern Mediterranean Region. He is Vice-Chair of WHO's

Guideline Review Committee and Executive Editor of the Eastern Mediterranean Health Journal, WHO Regional Office for the Eastern Mediterranean's flagship publication.

Previous positions include:

- Professor of Health Policy and Deputy Chancellor, Tehran University of Medical Sciences (TUMS), Islamic Republic of Iran
- Founding Director, National Institute of Health Research, Islamic Republic of Iran
- Honorary Visiting Professor, Imperial College, London, UK
- Honorary Professor, Shiraz University of Medical Sciences, Islamic Republic of Iran;
- Visiting Professor, School of Pharmacy, TUMS, Islamic Republic of Iran
- Methodological advisor, National Collaborating Centre for Acute Care (affiliated to the National Institute for Health and Care Excellence), UK
- Assistant Professor, London School of Hygiene and Tropical Medicine, UK
- Visiting Associate Professor, Aga Khan University, Pakistan
- Honorary Senior Research Fellow, Bangor University, UK.

He has led the development of strategic policy documents, advised national health policy committees and health insurance organizations and co-authored over 200 academic papers.



Meet the Speakers

The Clinical Trials Summit of Pakistan 2025

Dr. Vasee Moorthy

Dr. Vasee Moorthy is an infectious diseases physician, immunologist and product developer, with previous experience working as a clinical lecturer at the University of Oxford and for PATH in the USA. Dr Moorthy qualified as a physician with an undergraduate degree from the University of Cambridge and a clinical medicine degree from the University of Oxford, UK. He has a PhD in immunology gained during 3 years based at MRC Laboratories in The Gambia. He is currently serving as the Senior Advisor, R&D at World Health Organization and is lead for WHO guidance for best practices for clinical trials.



Dr. Arshad Altaf

Dr Arshad Altaf is a Technical Officer and acting team lead in the Research Promotion and Research Governance unit of the Science Information and Dissemination department of the WHO's Regional Office in Cairo.

He supports the research spectrum from the Regional Office in Eastern Mediterranean Region countries. This includes enhancing research proposal writing, scientific writing, and research ethics. He also manages the secretariat of the EMRO's Advisory Committee for Health Research and the Regional Research Ethics Review Committee. He is also the regional focal person for WHO Collaborating Centres for the EMR Region.

Dr Altaf's public health and academic career spans two decades of working in HIV and AIDS epidemiology, policy making, and country support. He has secured multiple research grants on a variety of topics related to communicable diseases. Dr Altaf has more than fifty publications in peer-reviewed journals, most of them as the primary author. He is also on the editorial board of Eastern Mediterranean Health Journal and is a reviewer for journals including BMJ, The Lancet, Plos and JPMA.



Meet the Speakers

The Clinical Trials Summit of Pakistan 2025

Dr. Akbar Fotouhi

He is an MD and a Professor of Epidemiology, who is actively involved in conducting clinical trials. With over two decades of experience, he has played a crucial role in designing and executing numerous clinical trials. He is a member of the National Committee of Medical Research Ethics and a member of the Clinical Trials Committee of the Food and Drug Organization of Iran. He is also a member of WHO's Technical Advisory Group on Development of Guidance on Best Practices for Clinical Trials.



Dr. Obaidullah, PhD, MPH

Dr. Obaidullah is a pharmacist with a PhD degree in Pharmaceutical Sciences and Master of Public Health with about 24 years professional experience and is associated with Drug Regulatory Authority of Pakistan since 2001. Presently working as Director (Pharmacy Services) responsible to supervise clinical trials, Pharmacovigilance, AMC and other Pharmacy Services related matters.

DRAP's Management Representative for ISO 9001:2015 Certification of DRAP achieved successfully in 2019. Successfully completed various professional trainings nationally and internationally and is a facilitator for training regulators and professionals from industry in field of pharmaceutical product development, stability studies, CTD, vendor qualification, GMP audit etc. Honored to be part of WHO HQ Regulatory System Strengthening team for cGBT assessment of various NRAs for their regulatory functions. He is part of drafting group for preparation of WHO guidelines on regulatory preparedness for vaccine non-producing countries and guideline on Biopharmaceutics Classification System (BCS) based Bio- waivers.



Meet the Speakers

The Clinical Trials Summit of Pakistan 2025

Prof. Dr. Shahrukh Hashmi

A global key opinion leader in the field of cancer, stem cells and Artificial Intelligence, Prof. Shahrukh Hashmi currently directs the Research at the Department of Health, Abu Dhabi, UAE; he practices as a professor of medicine at the Mayo Clinic (Minnesota, US) and is a professor (adjunct) of Computer Vision at MBZUniversity of Artificial Intelligence (Abu Dhabi, UAE). He chairs many international professional committees/groups including being the Chair of the Worldwide Network for Blood and Marrow Transplant's (WBMT) Global Emergencies Committee (Geneva, Switzerland), Founding Chair of the American Society for Transplantation and Cellular Therapy Survivorship SIG (Chicago, Illinois, US), and Ex Co-Chair of the Center for International Blood & Marrow Transplant Registry's (CIBMTR) Health Services Committee (Milwaukee, Wisconsin, US).



He was Medical Director of Research at SSMC/Mayo Clinic (Abu Dhabi, UAE), and the Chairman of the Dept. of Hematology/Oncology at SSMC(Mayo) Abu Dhabi, and the Chairman of SEHA Oncology Council UAE. He graduated from Baqai Medical University with top honors, receiving the Best Graduate Gold Medal from the President of Pakistan, and then received master's degree (MPH) from Yale University, Connecticut, US. He is triple boarded from the US, being Diplomat of the American Board of Preventive Medicine/Public Health, Internal Medicine, and Hematology. He has served as PI or Co-PI on many industry-sponsored and NIH-sponsored trials. His research interests include premature Aging Biology, Artificial Intelligence, and Cellular therapies (CAR-T cells and Gene Therapy). He is also involved in Stem Cell Therapeutics, particularly in regenerative hematology. He has authored >350 articles in peer-reviewed journals, including in JAMA Oncology, Lancet Hematology, and NEJM, and has >12,000 citations. His achievements include establishing the first BMT survivorship program of Mayo Clinic in Minnesota, establishing the first Clinical Trials of Saudi Arabia at King Faisal Specialist Hospital & Research Center (KFSHRC) in Riyadh, KSA, and establishing the UAE's first Clinical Trials Unit (CTU) at SSMC/Mayo Clinic in Abu Dhabi, UAE. He also utilized anti-aging drugs for First-in-Human Trials approved as IND from the USFDA and continues to serve as PI or Co-PI on Aging trials on Healthspan and lifespan.

As an established scientist in Cell & Gene Therapy, along with lifespan/longevity and Artificial Intelligence, Prof. Hashmi is frequently invited to international forums to deliver plenary talks and has delivered >80 invited lectures/presentations at international forums. Prof. Hashmi is also active as a Board/Advisory Board Member of many organizations including Make-A-Wish Foundation UAE, Cancer Patient Care Society (Rahma) UAE, Rose Nwatu Cancer Foundation (US/Nigeria), Emirates Thalassemia Society UAE, Make-AWish International's Advisory Board, besides being the Associate Editor of Journal of TCT.

Meet the Speakers

The Clinical Trials Summit of Pakistan 2025

Dr. Iftekhar Khan

Dr Iftekhar Khan has over 20 years of experience working in clinical trials. He has held academic posts in Medical Statistics and Health Economics at University College London, King's College London, University of Oxford and currently at the University of Warwick. Prof Khan was also a former Expert Statistical Assessor at the Medicines Health Regulation Agency (MHRA , UK) and The European Medicines Agency (EMA) where he assessed the evidence for multiple drugs and devices in multiple diseases areas, until November 2024. He was also the designated expert for evaluating submissions in Artificial Intelligence and Machine Learning and has contributed towards multiple EMA guidelines and publications. He is the author of 3 published books in Economic Evaluation of Cancer Drugs (Chapman & Hall, 2020) and Design & Analysis of Clinical Trials (Chapman & Hall , 2015) and

Understanding Artificial Intelligence and Machine Learning Applications in Health Research: Clinical Trials, Real World Data and Health Technology Assessment" (Chapman & Hall, 2025) as well as over 100 peer reviewed publications in clinical trials, statistics and health economics.

Prof Khan also sits on the UK Medical Research Council's (MRC) Panel of Experts in Applied Global Health and is also Chair of the Advisory Board to Regulatory Scientific & Health Solutions (www.r-s-s.com) ; A member of the advisory board for the EU Horizon project on "Unlocking Real World Data using Artificial Intelligence and Machine Learning (www.real4reg.eu) and also an advisory board member for several AI & ML technology private and public sector bodies. Dr Khan was also a member of the UK Health Security Agency (UKHSA) and a visiting faculty member of the Community and Health Sciences (CHS) at the Aga Khan University.



Meet the Speakers

The Clinical Trials Summit of Pakistan 2025

Dr. Essam Kerwash

Essam Kerwash is an expert clinical pharmacology assessor at the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom. Essam obtained his PhD in Clinical Pharmacology from University of London studying the interindividual variabilities in response to anti-cancer drugs. He received post-doctoral training at Barts Cancer Institute where his research was focused on the discovery of novel biomarkers that can predict activity/toxicity of the cytotoxic agents using Omics approach. At the MHRA, Essam assessed the clinical pharmacology aspects of license applications to support early patient access to number of innovative medicines. Essam is recognised for expertise in modelling techniques such as population and physiologically based modelling where he contributed to national and ICH M15 model informed drug development guideline. Essam is co-leading an active research program investigating the use of modelling to support dose optimization for medicines commonly used during pregnancy and lactation.



Audrey Ooi

Audrey is the Head of Business Development at Clinical Research Malaysia (CRM). She has over 12 years of experience in the clinical research field, with cross-functional roles in marketing, project management, stakeholder engagement, corporate communication, and medical writing. At CRM, she is responsible for growing industry-sponsored research in the country by strategizing and executing the organization's business plan, working closely with stakeholders and industry players to create a thriving clinical research ecosystem, and contributing to national policies, frameworks and guidelines to catalyze clinical trials in the country. She heavily contributed to the organisation's Phase I Realisation Project, an initiative which has enabled the conduct of early phase clinical trials in the country.



Meet the Speakers

The Clinical Trials Summit of Pakistan 2025

Dr. Iftekhar Mahmood

Dr. Mahmood holds a Bachelor of Pharmacy degree and a Ph. D. degree in Pharmaceutical Sciences (specialization in Pharmacokinetics) from University of Missouri at Kansas City, USA.

Dr. Mahmood has more than 25 years of US FDA experience in clinical pharmacology related to small and large molecules (antibodies and non-antibodies, coagulation factors, & immunoglobulins). He was the member of several working groups in FDA which wrote guidance for industry.

Dr. Mahmood has published more than 130 research papers in peer-reviewed scientific journals. He has also edited and wrote several scientific books.

Since September, 2019, Dr. Mahmood has been an independent clinical pharmacology consultant.




Dr. Aamir Jafarey

Dr. Aamir Jafarey is Professor at the Centre of Biomedical Ethics and Culture, Pakistan.

He teaches in the Postgraduate Diploma and Master's programs of the centre, and does research.

He is past member of the National Bioethics Committee and past member of WHO EMRO Ethics Review Committee. Since 2017,

He is also Co-Director of NIH-FIC funded CBEC-KEMRI Bioethics Training Initiative in Kenya.



Meet the Speakers

The Clinical Trials Summit of Pakistan 2025

Dr. Faiza Bashir

Dr. Faiza Bashir is the Research Director and National Focal Person of the National Bioethics Committee (NBC) at the Health Research Institute, National Institute of Health (NIH) Pakistan. A seasoned medical professional with a post-graduate specialization in Field Epidemiology and Bioethics, Dr. Bashir holds a Bachelor's degree in Medicine from Khyber Medical College. Her career trajectory at NIH (formerly Pakistan Health Research Council - PHRC) has seen her rise from Medical Officer and National Coordinator of the NBC to her current leadership position as Research Director.

Dr. Bashir has been instrumental in strengthening ethical frameworks for clinical trials in Pakistan. Her key contributions include developing Clinical Trials Management Guidelines and the Clinical Validation Protocol for Electromedical Devices, alongside her

expertise in the ethical oversight of clinical research. As a prolific researcher and grant awardee, Dr. Bashir has secured funding from prestigious organizations, including the BMGF, CDC, WHO, and the Government of Pakistan. She has led and participated in groundbreaking public health research and has authored numerous publications in peer-reviewed journals. Her writings span NBC guidance documents, DRAP protocols, and Data Safety Monitoring Boards (DSMBs). Her contributions extend to public health initiatives, including implementing the first-ever Standard Operating Procedures for Point of Entries at Islamabad International Airport during the COVID-19 pandemic.

Dr. Bashir's advocacy for ethical research and clinical trials is well-recognized nationally and internationally. She has represented Pakistan at global platforms such as the Global Forum for Bioethics in Research, and has been invited to present at conferences, workshops, and forums, underscoring her strong presentation and leadership skills.

Dr. Bashir's role as a permanent NBC representative in the Drug Regulatory Authority of Pakistan highlights her commitment to fostering ethical research practices. Her experience in inter-sectoral coordination, stakeholder engagement, and collaboration with national and international entities has significantly contributed to advancing clinical trials and bioethics in Pakistan. She has led NBC for conducting first ever human trials review and approval process of Pakistan manufactured medical devices like ventilators. She has remained instrumental in establishing frameworks for rapid reviews during pandemic at NBC, adverse event reporting, Clinical validation studies and IRBs registration in Pakistan through NBC.



Meet the Speakers

The Clinical Trials Summit of Pakistan 2025

Dr. Khalid Matin

Professor of Internal Medicine, VCU School of Medicine; Associate Director for Global Oncology, VCU Massey Comprehensive Cancer Center; Member of the Developmental Therapeutics Research Program, VCU Massey Comprehensive Cancer Center

Dr. Matin is a board-certified medical oncologist and clinical researcher who specializes in the study and treatment of gastrointestinal (GI) cancers. He has developed several clinical trials for GI cancers and has served as the principal investigator and coinvestigator on various colorectal cancer trials. Dr. Matin oversees Massey's partnerships with third-party hospitals and oncology practices and manages the clinical trials program for the statewide Clinical Research Affiliation Network.

Dr. Matin is currently the Principal Investigator for the Minority Underserved NCORP grant from the National Cancer Institute. Dr. Matin serves as the Chair of the ASCO Clinical Trials Access and Inclusion Task Force. Dr. Matin serves as the Associate Director for Global Oncology at Massey Comprehensive Cancer Center, where he is responsible for driving the strategic direction of Massey's global oncology initiatives and expanding the center's reach in the fight against cancer worldwide. Dr. Matin received his medical degree from Aga Khan University Medical College in Pakistan before completing a residency in internal medicine at Hennepin County Medical Center and a fellowship in hematology-oncology at the University of Pittsburgh Cancer Institute.



Dr. Shalaan Beg, MD MBA FASCO

Senior Advisor for Clinical Research at the National Cancer Institute. He is leading initiatives to use technology-enabled, decentralized, trial services to increase access for oncology trials. He has been invited to speak on this topic at AACI, ECOG-ACRIN, AACR and ASCO. Dr. Beg is a member of the Bloomberg New Economy International Cancer Coalition and White House Cancer Moonshot committee on innovation in trial delivery. Previously, he led clinical trial operations at UT Southwestern, where he also developed the pancreatic cancer program and served as the Principal Investigator of the Experimental Therapeutics Clinical Trial Network (ETCTN) grant.



Meet the Speakers

The Clinical Trials Summit of Pakistan 2025

Dr. James Kyle Bryan

Dr. James Kyle Bryan is the Chief Medical Officer for IQVIA Biotech and the Global Head of the IQVIA Hematology-Oncology Center of Excellence. He has diverse experience in drug discovery and development in the biopharmaceutical industry spanning almost 30 years. In his role with the Center of Excellence, Dr. Bryan leads a team of therapeutic and operational subject matter experts providing innovative medical and therapeutic insights to our sponsors, and as CMO for IQB, he has a particular focus on the needs of emerging biopharma and biotechnology clients. Prior to joining IQVIA in 2017, Dr. Bryan has served as Chief Medical Officer for VentiRx Pharmaceuticals, a Seattle-based immuno-oncology biotech, as Vice President of Medical Affairs for SeaGen (formerly Seattle Genetics), and Vice President, Global Drug Development at PPD, Inc. He was honored in 2021 as one of the PharmaVoice 100, recognizing the most inspiring people in the life-sciences industry. Dr. Bryan is board-certified in Medical Oncology and Hematology. His fellowship training was completed at the University of Washington, where he remains active in clinical work, holding an appointment on the clinical faculty of medicine. He received his B.S. in Biochemistry and his M.D. from Louisiana State University.



Mahira El-Kholy

Global Project Manager

Mahira ElKholy is a clinical research professional with 10 plus years of experience across multiple therapeutic areas including Cardiovascular, Oncology, Ophthalmology, Hematology and Respiratory Diseases, Rare Diseases in Phase II -IV. Her experience also includes working on global and regional clinical trials in South Asia, Europe, Australia and other regions. Her significant roles at Syneos Health, IQVIA CRO, and Sanofi Pharma, where she excelled in project management, budget oversight, and team leadership. Mahira holds a bachelor's degree in pharmacy and biotechnology with ongoing Master's Degree for Project Management from Northeastern University. She is recognized for her expertise in managing global trials, ensuring compliance, and delivering high-quality results within specified timelines and budgets.



Meet the Speakers

The Clinical Trials Summit of Pakistan 2025

Dr. Mazhar Jaffry

Dr. Mazhar Jaffry is a distinguished businessman, philanthropist, and global pioneer in clinical research with over 25 years of experience in the pharmaceutical industry and more than a decade specifically in clinical research. As a visionary leader, he has founded 15 multinational companies, rapidly expanding over all seven continents, revolutionizing industries and creating innovative solutions that transform lives.

Among many others, Dr. Jaffry is also the founder of Revival Research Institute, a leading organization conducting innovative clinical trials to address complex diseases and improve global health outcomes. He has played a pivotal role in building organizations such as Wellvana, which is transforming healthcare delivery by enabling physicians to provide value-based care and

empowering patients to achieve better health outcomes. In addition, he established Digital Auxilius (DAX), a cutting-edge digital agency specializing in web development, marketing, software development and branding. Minerva Research Solutions is another notable establishment of Dr. Jaffry. It is a clinical trial management service provider, growing into CRO space in Asia and beyond. Together, these companies employ over 300 individuals, fostering global employment opportunities and driving progress in their respective industries.

Beyond his professional achievements, Dr. Jaffry is deeply committed to philanthropy. His initiatives include building hospitals and orphanages such as an orphanage in Haiti for women. He is at the forefront of women empowerment as he is working on establishment of education and support systems for women in rural areas of Pakistan.

Dr. Jaffry's relentless dedication to transforming lives through research and innovation continues to inspire global progress in healthcare and beyond.



Meet the Speakers

The Clinical Trials Summit of Pakistan 2025

Dr. Um-e-Sughra

A dynamic leader in healthcare research, currently serving as the Director of Research at Al-Shifa Research Centre driving high-impact International Clinical trials. She spearheaded 7 International trials, establishing Al-Shifa Research Centre as a top-performing Clinical Trial Site Nationally and Internationally. She fostered partnerships with global and local stakeholders, expanding Research

Centre influence. Also, an academician who enjoys teaching experience of more than 17 years. She has numerous research papers on her credit published in prestigious national and international research journals. She is also a part of AlShifa faculty as Professor of Public Health. Prof. Dr. Ume Sughra has an impressive publication record in top-tier medical journals, focusing

on multiple public health areas. She has authored over 50 peer-reviewed articles in indexed journals, addressing pressing public health concerns. Her work has significantly contributed to advancing public health knowledge and informing evidence-based practices.



Dr. Farah Asif

Farah Asif is leading Clinical Research Office and Clinical Trial Unit in Shaukat Khanum Memorial Cancer Hospital & Research Centers (SKMCH&RC), Pakistan. She has done M.B., B.S. (Nishtar Medical College, Multan), Pakistan; MSc Clinical Trials (London School of Hygiene and Tropical Medicine, London, UK); European Fellowship in Research Ethics (EFRE) organized by the Good Clinical Practice Alliance – Europe (GCPA) and the Strategic Initiative for Developing Capacity in Ethical Review (SIDCER) in cooperation with the Global Health Institute, University of Antwerp (GHI-UA), and the Middleton Foundation for Ethical Studies (MFES). She is leading the Coordination Centre of The Global Health Network Pakistan, based at SKMCH&RC. She has worked in various collaborative capacities with multiple national and international bodies, including Bill and Melinda Gates Foundation.



Meet the Speakers

The Clinical Trials Summit of Pakistan 2025

Dr. Maimoona Siddiqui

After graduating from Dow Medical College, Karachi, Dr. Maimoona completed her Fellowship from College of Physicians and Surgeons, Pakistan and is currently working as a Consultant Neurologist at Shifa International Hospitals Ltd., Islamabad.

She also serves as the Director of Medical Education and Research at Shifa International Hospital, Islamabad, Pakistan.



Dr. Zulfiqar Umrani

Director Clinical Trials Unit, Director ORIC, Ziauddin University

Dr Zulfiqar is the founding Director of Ziauddin CTU which he helped to establish in 2022. It is a DRAP approved CTU running multiple successful trials. Some of these international trials have won accolades such FDA 'breakthrough therapy' designation. Dr Zulfiqar believes in participatory approaches, that is why Ziauddin CTU has launched Pakistan's 1st Patient Public Involvement and Engagement (PPIE) Group. He has a PhD from France and his areas of interest are Public Health, Climate Change and Sustainable Development.



Meet the Speakers

The Clinical Trials Summit of Pakistan 2025

Dr. Izhar M. Hussain

Dr. Izhar Hussain is the CEO & Management Director of Dow Institute of Life Sciences (DILS), Dow University of Health Sciences. In recent past, Hussain served as the Director of the Institute of Business and Health Management at the same University for five years.

Earlier, Dr. Hussain was the Director of the Center for Executive Education at the Institute of Business Administration (IBA) for ten years. Before that, he spent over 25 years serving various MNCs in different management positions. His last engagement before joining IBA was with Abbott Pakistan as Director of Business Excellence of a region covering South Korea, India, UAE, Saudi Arabia, and Egypt with Pakistan. Moreover, he has served in different positions in marketing, sales, supply chain, brand management,

regulatory affairs, business excellence, and business development. Earlier, he had been associated with MOH Libya and coordinated WHO/UNICEF for their projects in the Eastern Mediterranean Region.

He holds a Ph.D. in Pharmaceuticals and an MBA in Marketing. He is also a Certified Director (IBA/DTP-0104), a Certified Auditor for the ISO-9000, and a Certified Six Sigma Black Belt. He reviewed conference abstracts and manuscripts for the International Society for Pharmacoeconomics and Outcome Research from 2011 to 2018 and the Academy of Human Resource Development from 2010 to 2024.

He has been imparting training within and outside Pakistan and engaged with various business and pharmacy schools. He has also been in curriculum and academic program development at different educational institutions. He published papers in research journals, contributed book chapters, wrote articles in the general press, and supervised research projects and theses of postgraduate students.

Dr. Hussain is on the editorial board of the British Journal of Pharmacy (BJP-UK) and the Journal of Strategy and Performance (JSPM-Pakistan). He is the current Chairman Education Board of Fatimiyah Education Network (FEN) and a member of the Academic Council of Shahwalayat Educational Trust. He was the chairman of the Board of Directors of the Institute of Financial Markets (An institute formed under the SECP) from 2014 to 2022 and a member of the Board of Directors of the Pakistan Security Press Corporation (PSPC) from 2019 to 2021. He is also a member of the Board of Advisors of Transformation Professional Private Limited (TPPL).

He also worked closely with the National Business Education Accreditation Committee (NBEAC), the Higher Education Council, and the Sindh Higher Education Commission (SHEC). His team comprises members with extensive experience preparing and reviewing documentation for recognition and accreditation processes.



Meet the Speakers

The Clinical Trials Summit of Pakistan 2025

Dr. Naseer Ahmed, MBBS, PhD, FACC, FESC

An accomplished Associate Professor and Director of Research at RCD-RMI, Peshawar.

With a PhD and Postdoctoral Fellowship in Cardiovascular Sciences from the University of Verona, Italy, he has authored over 50 abstracts and research articles, achieving a cumulative impact factor exceeding 100.

Dr. Ahmed is an HEC-approved PhD Supervisor, and Head of the Clinical Trials Unit at Rehman Medical Institute, Peshawar. He also serves as a Visiting Researcher at the University of Verona, Italy, contributing to global cardiovascular research initiatives.



Dr. Masood Jawaid, MBBS, MCPS, MRCS (Glasg), FCPS (Surgery), MHPE

Dr. Masood Jawaid is an accomplished medical professional with extensive experience in medical education, research, and online education. He is trained as a General Surgeon and Medical Educationist, currently working as Director Medical Affairs at PharmEvo (Pvt) Ltd. He is also the Director of Institute of Leadership Excellence and Associate Editor of the Pakistan Journal of Medical Sciences (highest impact factor medical journal of Pakistan).

With over 125 published papers (h index: 32) and two authored books (Scientific Writing and Medical Writing), Dr. Jawaid is also an adjunct faculty member at various medical universities and conducts regularly conduct faculty development trainings.



Meet the Speakers

The Clinical Trials Summit of Pakistan 2025

Dr. Camilla Forssten

Dr. Camilla Forssten holds a Masters in Chemical Engineering from Åbo Akademi University, Finland and PhD in Electrochemistry from University College London, UK. With over 22 years of experience in the medical diagnostics industry, Camilla has held various positions in diagnostic product development. Her primary interest lies in Clinical Affairs, where she has specialized in the development of rapid diagnostic tests for various infectious diseases. Camilla has led a significant number of trials across various diseases, including HIV, Hepatitis B and C, Syphilis, Influenza, and Covid-19, supporting global regulatory approvals and contributing to peer-reviewed publications. She is part of the Abbott Rapid Diagnostics Infectious Disease business unit and is currently based in the UK. Camilla

finds great joy in collaborating with academic and industry partners to develop novel tests that enhance patient health and enable timely patient management through rapid point-of-care diagnosis.



Dr. Atika Shaheer

Dr. Atika Shaheer is a highly accomplished professional currently serving as the Director of Medical Regulatory and Pharmacovigilance at Novo Nordisk, Pakistan. With a wealth of experience in the pharmaceutical industry, Dr. Shaheer possesses expertise in diverse areas including Epidemiology, Emergency Medicine, Management, Healthcare Management, and Healthcare Frameworks.

Her credentials include an affiliation with the Life Management Institute (USA) within the context of Medical Insurance, a focus on Clinical Research, and a distinguished medical degree. Dr. Shaheer is dedicated to expanding avenues for clinical research and real-world evidence generation within Pakistan, particularly in Non-Communicable Diseases (NCDs).



Meet the Speakers

The Clinical Trials Summit of Pakistan 2025

Dr. Bin Chen, PhD

Dr. Bin Chen is the CEO of Huahui Health, an innovative biotech company focused on developing advanced therapies in antiviral and oncology fields. With over 20 years of experience in the biopharmaceutical sector, he has a proven track record of leading research and driving product development. Under his leadership, Huahui Health has secured significant funding and advanced multiple "first-in-class" and "best-in-class" therapeutics, including Libevitug, which has received breakthrough therapy designation for chronic hepatitis delta in both China and the U.S.

Before joining Huahui, Dr. Chen was the CEO of Syngentech Co., Ltd., where he applied synthetic biology to gene and cell therapy development, achieving the dual submission of the world's first the

Head of Translational Sciences for Bayer in Asia, overseeing clinical pharmacology and trial operations. Dr. Chen's prior experience includes over a decade at Amgen and Johnson & Johnson, where he rose from scientist to Head of Early Development for Biologics in emerging markets. He holds a Bachelor's degree in Mechanical Engineering from Nanjing University of Aeronautics and Astronautics, a Ph.D. in Biomedical Engineering from the University of Nevada, and completed postdoctoral research at The Ohio State University College of Pharmacy.




Dr. Yousuf Hasan Khan

Dr Yousuf Khan is a Medical Graduate with a Diploma in Diabetes Mellitus. He has approximately 27 years of experience in the Pharmaceutical Industry in the areas of Sales, Sales Training, Marketing, Regulatory, Clinical Trials/Operations and Medical Affairs. Currently he is the Medical Director of GSK Pakistan and based in Karachi.

In a previous role as Head of Clinical Operations he managed a number of Clinical Trials for GSK. Mostly conducting Phase 3 clinical research but also initiated some bioequivalence and epidemiology studies to support the commercial development of new molecules, including some vaccines.

Dr Yousuf Khan also has experience in Public Health research. He has supported some new initiatives of simplifying clinical development using technology to speed up the process of research and development.



Meet the Speakers

The Clinical Trials Summit of Pakistan 2025

Dr. Nadim-ur-Rehman

With over 27 years of experience in the pharmaceutical and healthcare industries, Dr. Nadim-ur-Rehman is currently serving as the Head of Medical Affairs for Pakistan and Afghanistan at Hoechst Pakistan Limited.

He has held key leadership roles in some of the most renowned organizations including leading Medical and Regulatory Affairs at ICI Pakistan, Area Medical Director for Abbott Nutrition in the Asia Pacific region, and held senior positions at Hilton Pharma, Wyeth, and GSK. His expertise spans clinical practice, regulatory affairs, and business management, with significant contributions at ATCO, Halim Hospital, Aga Khan Hospital, and Ziauddin Hospital. Beyond his leadership roles, Dr. Nadim-ur-Rehman is a published researcher with seven papers in internationally recognized journals.

His contributions to the field have been recognized with prestigious awards, including the President's Award (Runners-up) at Wyeth and the Luminary Award for R&D at Abbott Nutrition. Dr. Nadim-ur-Rehman is also deeply involved in advancing pharmaceutical medicine and clinical research. He is an Associate Faculty member of Pharmaceutical Medicine at the Royal College of Physicians, UK, the President of the Pakistan Association of Pharmaceutical Physicians, and an active member of Pharma Bureau's Clinical Research Sub-Committee. With a remarkable career dedicated to innovation, research, and leadership in healthcare, Dr. Nadim-ur-Rehman continues to shape the future of medical affairs and pharmaceutical research.



Dr. Ahmed Nawaz

With over 23 years of experience in the pharmaceutical industry, Dr. Nawaz has expertise spanning medical affairs, clinical trials, marketing, and sales. His strong academic foundation includes an M.B.B.S., an MBA, and a Professional Certificate in Medical Affairs from King's College London.

Dr. Nawaz plays a pivotal role in defining and implementing medical affairs and compliance strategies in alignment with applicable laws, codes, and industry guidelines. A strong advocate for innovation and outcomes research, he has 14 publications in national and international journals and has been recognized with the W.E. Upjohn Award of Innovation and the Asia Outcomes Research Projects award.



Meet the Speakers

The Clinical Trials Summit of Pakistan 2025

Dr. Murtaza Hussain

With a qualification of M.B.B.S. and M.B.A., Dr. Murtaza Hussain has been trained in reputed institutes like the Aga Khan University Hospital and University of Aberdeen, Scotland. He has a rich work experience with companies like Abbott and Novartis with experience of clinical research from both the sponsor's and the recipient's end. He is also an independent reviewer in renowned international journals.



Syed Munawar Ali

Syed Munawar began his career as a Clinical Research Assistant, focusing on raising awareness and providing training in clinical trials. He played a pivotal role in organizing Pakistan's first international Clinical Trial Course, benefiting over 2,000 students. As a project manager, he oversaw more than 70 national and international clinical studies, including 21 FDA-approved bioequivalence studies.

Since 2019, Syed Munawar has been leading IQVIA-RDS in Pakistan, driving rapid growth while setting new benchmarks in clinical research standards. His dedication to professional development extends beyond his work, as he offers ICH-GCP and Good Documentation Practice training, part of his CSR efforts to create better opportunities for Pakistan's youth.



Dr. Khushbukhat Khan

Dr. Khushbukhat Khan is the Oncology Lead at Trials360, managing preclinical and clinical projects. With ~60 scientific publications, she serves on the editorial boards of BMC, Springer Nature, and Frontiers. She is also a co-editor of an upcoming book on precision oncology and guest editor for a special issue on lncRNAs in cancer in Frontiers in Oncology.



Meet the Speakers

The Clinical Trials Summit of Pakistan 2025

M. Khurram Zaki Khan

M. Khurram Zaki Khan is a trailblazer in outsourced clinical research in Pakistan. As the Founder and CEO of Dimension Research® CRO & SMO, he leads one of the country's first and largest LARQA ISO 9001-2015 certified, DRAP-approved contract research, site management, and patient support service providers.

A Microbiologist by profession, he holds a Master's degree from the University of Karachi (1989) and a Postgraduate Diploma in Bacteriology from Victoria University, Manchester, UK. With over 30 years of expertise in clinical research, quality assurance, pharmacovigilance, medico-marketing, and patient support services, he has worked extensively with multinational organizations and his own company.



Fahad Hussain

Fahad Hussain is the CEO of the Praetorian Group, a company deeply rooted in Pakistan's cargo industry since 1975. Coming from a family of industry pioneers, he joined the business in 1997, bringing a fresh perspective and a global outlook.

Educated at Karachi Grammar School and The Wharton Business School at the University of Pennsylvania, Fahad quickly took charge of the family's business, playing a pivotal role in expanding global partnerships. Under his leadership, the group represents some of the world's largest logistics and aviation entities in Pakistan.

Recognising the growing demand for specialised logistics in life sciences, Fahad partnered with World Courier, USA (AmerisourceBergen) in 2004, who are global leaders in medical logistics for clinical trials and commercial supply chains, providing GxP-compliant cold chain transportation. This strategic collaboration further solidified Fahad's reputation as an industry innovator.

With over two decades of experience, he is regarded as a leading figure in Pakistan's freight and logistics sector.



Meet the Speakers

The Clinical Trials Summit of Pakistan 2025

Syeda Azka Wase

I am a seasoned professional with extensive global experience in establishing strategies and pathways for conducting clinical trials in Low- and Middle-Income Countries (LMICs). Committed to our mission of creating access to Clinical Development Programs, I have successfully brought global clinical research initiatives to Pakistan and other underserved regions in Asia and Africa.

With an initial education as a Doctor of Pharmacy, my career has been meticulously shaped to build the landscape and capacity in these countries, fostering better patient outcomes and treatment options for underserved populations. My collaborations and interactions with global public health policy professionals have enabled me to implement innovative interventions in new countries through complex and specialized clinical trial solutions.

My association with the largest Contract Research Organization (CRO) in Pakistan has empowered me to attract global-level drug developers, biopharmaceutical companies, and public health organizations to extend their operations in Pakistan. This has led to significant improvements in patient care and access to advanced treatments for those in need.



Dr. Ahmed Kamal, PhD

Dr. Ahmad Kamal, a Ph.D. in Pharmaceutics, is an experienced clinical research professional with over 14 years in the pharmaceutical and CRO industries. As a Clinical Project/Operations Manager at OrcaTrials, he oversees team development, project execution, and regulatory compliance. His expertise spans clinical trial management, quality assurance, and translational research, having led multiple global and local studies in Oncology, Infectious Diseases, and Metabolic research. With extensive experience in audits, quality management, and public health programs, he plays a key role in advancing clinical research infrastructure and operational excellence in healthcare industry.



Meet the Speakers

The Clinical Trials Summit of Pakistan 2025

Dr. Timo Tolppa

Dr Timo Tolppa is a PhD student at the University of British Columbia working to incorporate trials into routine clinical care in intensive care units across South Asia. He trained and worked as a junior doctor in the United Kingdom, and has experience as a regional clinical trial manager, public engagement coordinator and mentor in global health partnerships. Dr. Tolppa has an interest in pragmatic trials, real world data and research ethics, and volunteers for the charity Global Health Film.



Shelly Sedhigi

Shelly Sedhigi is a seasoned clinical research professional with extensive experience in developing and expanding clinical research programs across the Middle East, including Dubai, Saudi Arabia, and other international markets. As the founder of Qcare Health Research Corporation, she has demonstrated expertise in providing proprietary education and training content, collaborating with organizations such as the Association of Clinical Research Professionals (ACRP). Shelly's strategic vision and deep understanding of regional business practices have positioned her as a key liaison in delivering globally recognized clinical research training. She is committed to elevating clinical research standards and making high-quality training accessible to professionals worldwide.



Meet the Speakers

The Clinical Trials Summit of Pakistan 2025

Dr. Fyezah Jehan

Dr Jehan is a Pediatrician and an epidemiologist, with a decade of experience of conducting research in Maternal Newborn and Child Health in Pakistan. Her specific areas of interest and expertise are vaccines and vaccine preventable illnesses like childhood pneumonia and new approaches to its diagnosis and management, maternal health and its impact on the young infant, infections in the newborn, maternal and child mortality surveillance, human biorepository in low income settings and biomarker discovery.

She is a strong advocate of young talent and a mentor and advisor to numerous undergraduate, graduate and postgraduate students and senior and junior staff and faculty at her university. She serves as the Chair of the Department of Paediatrics and Child Health.



Dr. Isabel Potani

Dr. Isabel Potani is a child and maternal health researcher with a nursing background. She has extensive experience in designing and implementing clinical trials in low- and middle-income countries (LMICs), particularly focused on addressing malnutrition. Her research has significantly contributed to the development of WHO guidelines for the treatment of wasting.



Meet the Speakers

The Clinical Trials Summit of Pakistan 2025

Prof. Sir. Andrew Pollard, FMedSci FRS


Professor Sir Andrew Pollard FMedSci FRS is Director of the Oxford Vaccine Group and Ashall Professor of Infection and Immunity at the University of Oxford and consultant in paediatric infectious disease at Oxford Children's Hospital. He is chair of the UK Joint Committee on Vaccination and immunisation (since 2013) and was a member of WHO's SAGE 2016-2022 and is a member of Council of the Academy of Medical Sciences. He received a knighthood in 2021 for services to public health.

Andrew's research has focussed on the understanding of childhood immunity and vaccine protection, testing vaccines against the encapsulated bacteria which cause meningitis, pneumonia, typhoid and paratyphoid and informing global immunisation policy.

He has pioneered the use of controlled human infection challenge models to investigate the biology of infections and to test vaccines for typhoid and paratyphoid. His research has included large epidemiological studies and vaccines trials in Europe, South Asia and Africa involving more than 100,000 children. His seminal work on typhoid supported the WHO prequalification of a new typhoid conjugate vaccine and WHO recommendations for its use in countries with a high burden of disease.

He led testing of influenza vaccines for children in the 2009 pandemic, new vaccines for Ebola in the 2014/15 outbreak, and clinical development of the Oxford-AstraZeneca COVID19 vaccine in the 2020/21 coronavirus pandemic for which the team were awarded the Royal Society's Copley Medal.

He has supervised 50 PhD students and his publications include over 750 manuscripts and books on various topics in paediatrics and infectious diseases. He has received multiple awards including the James Spence Medal of the Royal College of Paediatrics and Child Health, The Rosen von Rosenstein Medal of the Swedish Society of Medicine and the Bill Marshall Award of the European Society for Paediatric Infectious Disease.



Meet the Speakers

The Clinical Trials Summit of Pakistan 2025

Dr. Salman Kirmani

Dr. Salman Kirmani is a Medical Geneticist & Pediatric Endocrinologist associated with the Aga Khan University as a Professor of Paediatrics and Medicine, and Chair (Division of Women & Child Health), and the Director of the Center of Excellence for Women & Child Health. He is also the Interim Director of the Human Development Program at AKU. Dr. Kirmani did his MBBS (MD) from Dow Medical College, Karachi followed by Residency & Fellowships from Mayo School of Graduate Medical Education, Mayo Clinic, Rochester, MN. Dr. Kirmani is certified by the American Board of Medical Genetics (Clinical Genetics), and the American Board of Pediatrics (General Pediatrics & Pediatric Endocrinology). He was on faculty at the Mayo Clinic till he returned to Pakistan to join the Aga Khan University in 2014.



Dr. Syed Asad Ali

Dr. Asad Ali is the Chair Department of Community Health Sciences and The Noordin Noormahomed Sheriff Endowed Chair, Professor of Pediatrics and Community Health Sciences. He is an alumnus of AKU Medical College and obtained his advanced clinical training in Pediatrics at Duke University, and Fellowship in Pediatric Infectious Diseases, and Masters in Public Health at Vanderbilt University, USA.

His research interests pertain broadly to pediatric public health in developing countries, especially infectious diseases, vaccines, and childhood malnutrition in Pakistan and the region. His group is particularly interested in finding sustainable solutions to these problems grounded in our societies. He has led many clinical studies with funding from institutions like the Bill and Melinda Gates Foundation, NIH USA, Welcome Leap, and CDC USA to address these problems using cutting-edge scientific approaches.




Meet the Speakers

The Clinical Trials Summit of Pakistan 2025

Prof. Javed Akram, MRCP(UK), FRCP(London), FRCP(Glasgow), FRCP(Edin), FACC(USA), FACP(USA), FASIM(USA)

Professor Javed Akram is a highly reputed Professor of Medicine in Pakistan, currently serving as the Minister of Health, Punjab. He is the author of six books and 400 research papers presented at international and national meetings, symposia, and seminars, with a cumulative impact factor of over 700, which is the highest in Pakistan for a clinician. He has rendered valuable services through participation in numerous academic, administrative, and clinical committees. He is a clinician, a laboratory researcher, a medical educationist, and a health delivery administrator. Additionally, he is an active laboratory research leader, presently leading a group working on cloning human pharmaceutical protein genes. His recent efforts have resulted in the cloning of human interferon genes in *E. coli* and yeast, serving as source material for the semi-commercial production of interferon, a therapeutic agent against hepatitis B and C. His research also focuses on the regeneration of bone marrow and adipose tissue-derived stem cells to exploit their potential in repairing burn-damaged skin. He is leading a group of researchers as the principal investigator, who have successfully cloned more than 27 pharmaceutical proteins, including insulin, growth hormones, CSF, and erythropoietin. He is also the principal investigator of the largest-ever study being conducted in Pakistan on A4P and is overseeing many other research projects in the same capacity.



Professor Javed Akram has also served as Minister for Health and Social Welfare, Bait-ul-Maal, Government of Punjab (February 2023 to March 2024). He is the founding Vice Chancellor of Shaheed Zulfiqar Ali Bhutto Medical University (SZABMU), which was established through an Act of Parliament on 21st March 2013. The Vice Chancellor was appointed by the Chancellor, the President of Pakistan, on 7th January 2014. The Pakistan Institute of Medical Sciences (PIMS) in Islamabad is the constituent hospital of SZABMU. He has made tremendous contributions in organizing the entire structure of the university and is persistently working to make it a model university, second to none. SZABMU now offers structured residency training programs in 32 disciplines of medicine, surgery, and dentistry. Moreover, M.Phil. and Ph.D. programs are also being offered in twelve disciplines of basic medical sciences. A number of MOUs have been signed to offer post-graduate structured training programs in clinical disciplines, with qualifications equivalent to international medical qualifications like FRCP, MRCP, and Diplomate of the American Board.

He has also served as Vice Chancellor of the University of Health Sciences, Lahore; Founding President of the Inter-University Board of all medical universities in Punjab; Founding President of the Pakistan Society of Internal Medicine; and Chairman of the World Ramadan Study.

Professor Akram has significantly contributed to the delivery of quality healthcare to the ailing masses free of cost. As Principal of Allama Iqbal Medical College and Chief Executive of Jinnah Hospital, Lahore, he set an enviable precedent by ensuring 100% free medical care for patients. He established a diversified range of specialties in the hospital, including departments of cardiac surgery, hepatology, nephrology, endocrinology, vascular surgery, clinical genetics, rheumatology, immunology, medical education, and directorates of nursing, obstetrics and gynecology, radiology, and pathology, along with a burn and reconstructive surgery center. Another significant contribution is the establishment of medico-legal and non-medico-legal autopsy protocols at Jinnah Hospital, making it a leader in hospital autopsy in Pakistan.

Professor Akram has been selected as Chairman of the WHO Guideline/Expert Committee, and the second edition of the guidelines was recently published and disseminated worldwide.

Professor Akram has meticulously utilized corporate social responsibility; numerous MOUs were signed for the benefit of the institution, generating substantial funds for various institutions, thereby reducing the financial burden on the government exchequer.

As a consequence of his invaluable services to the profession, community, and outstanding research, Professor Javed Akram has been honored with numerous prestigious awards, including the Prime Minister's Gold Medal for research in the field of Parkinson's disease (1999), the Best Research Award (2005-06) by the National Academy of Medical Sciences, and the Tamgha-i-Imtiaz (2011) by the President of Pakistan. Recently, Professor Akram was nominated for the Excellence in Patient Care Award by the prestigious Royal College of Physicians of London.